Achieving the right dose remains one of the biggest challenges in ADHD treatment. Discover how individualized dose optimization could improve treatment continuity, patient adherence, and long-term outcomes.

Many Nordic life science companies have world-class science, yet struggle to attract the attention they deserve. In this exclusive Venture Road UK conversation, investor Altar Munis reveals what truly matters to UK investors—and why the right story can be just as important as the science itself.

Discover how leading players from the UK and Nordic life sciences ecosystems are joining forces to accelerate innovation and advance the future of Precision Health.

Last Thursday during Venture Road UK, companies from across the Nordics and the UK pitched in front of a mixed audience of investors and industry partners. Our warm congratulations to the winner of the pitch session, Christina Coughlin, CEO of Avacta, who is working on targeted cancer therapy delivery to improve efficacy while reducing side effects for patients.

As BIO International 2026 approaches, standing out requires more than breakthrough science. Discover how Ventures Accelerated helps Nordic life science companies transform visibility into strategic partnerships through targeted positioning, exclusive interviews, and global outreach.

Through our new partnership with AWA Sweden, we explore how strategic IP management can strengthen valuation, support funding, and prepare companies for successful partnerships and exits.

What makes a biotech partnership truly successful ? Beyond term sheets and deal structures, the strongest collaborations are built on trust, alignment, and a shared vision. Discover the human side of biotech partnering.

At InterPhex 2026, one challenge stands out: scaling complex biologics affordably. Just-Evotec Biologics is redefining the model with AI-driven design and continuous manufacturing — reshaping access to next-generation therapies.

In this episode of Discovery Matters by Cytiva, innovation is explored from both a scientific and deeply human perspective. Insights are shared on how AI, precision partnering, empathy, and behavioural insight are reshaping life sciences.

Explore how life science companies can benefit from thinking about their end goals from the very beginning. Featuring insights from industry experts, it highlights how early decisions around IP, strategy, and structure can shape long-term outcomes. A concise look at the perspectives shared ahead of The End Game seminar.

The Spring Salon marks the arrival of spring in the Nordics, an evening of connection, renewal, and art for the life science community. Join us on April 28 at Skeppsbron 10 as our space transforms into a gallery featuring Emma Jelk and Jullianne Jabol.

In metastatic colorectal cancer, where treatment options are limited, new approaches are urgently needed. At Charité Berlin, Professor Sebastian Stintzing is advancing a novel combination of immunotherapy and personalized vaccination—aiming to improve outcomes through smarter patient selection and innovative trial design.

Bridging Nordic scientific rigour with American ambition could be key to unlocking larger investments in life sciences. By combining deep expertise with bold capital strategies, investors like Flerie are helping catalyse bigger funding rounds and accelerating innovation from lab to market.

Building a biotech startup mirrors raising a child: a journey fueled by vision, uncertainty, and relentless commitment. From fragile beginnings to eventual independence, both evolve through phases of rapid growth, doubt, and transformation — requiring founders to nurture, adapt, and ultimately learn to let go as their creation takes on a life of its own.

PRESS RELEASE - A group of Nordic life science leaders will travel to the United Kingdom from 7 to 12 June as part of Venture Road UK, an initiative designed to strengthen collaboration between two of Europe’s leading life science ecosystems.

Global partnering in life sciences is entering a new era shaped by geopolitical shifts, financial pressure, and rapid innovation. In her latest column, Helena Strigård highlights how success now depends on global agility, strategic alliances, and the ability to move fast across markets. A must-read for understanding the new rules driving growth and opportunity in today’s biotech landscape.

From a single evening of generosity to life-saving action on the ground, the Impact Day Gala became more than a moment—it became momentum. The funds raised are now translating into critical neurosurgical missions, where expertise meets urgent need.

Featuring Diamyd Medical, the discussion explores a groundbreaking approach to preserving the body’s own insulin production through immune system research. A must-listen to understand how Swedish innovation is gaining momentum on the global stage.